Ann Lab Med.  2016 May;36(3):287-289. 10.3343/alm.2016.36.3.287.

Chronic Myeloid Leukemia With Rare Variant b2a3 (e13a3) BCR-ABL1 Fusion

Affiliations
  • 1Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea. saeam0304@yuhs.ac LEE.ST@yuhs.ac
  • 2Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Abstract

No abstract available.


MeSH Terms

Base Sequence
Bone Marrow/pathology
Fusion Proteins, bcr-abl/*genetics
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*genetics
Male
Middle Aged
Real-Time Polymerase Chain Reaction
Fusion Proteins, bcr-abl)

Figure

  • Fig. 1 (A) Agarose gel electrophoresis of multiplex reverse transcription (RT)-PCR product showing an atypical band of approximately 220 base pairs, suggesting the presence of the b2a3-type BCR-ABL1 fusion transcript. Lane M, bp markers; Lane Pat, reported patient with variant b2a3-type fusion transcript; Lane B, blank; Lane b2a2, positive control with b2a2 fusion transcript. (B) cDNA sequence results of the RT-PCR product demonstrating the b2a3-type fusion transcript (reference sequence: BCR, NM_004327.3; ABL1, NM_005157.5).


Reference

1. Liu LG, Tanaka H, Ito K, Kyo T, Ito T, Kimura A. Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3. Am J Hematol. 2003; 74:268–272. PMID: 14635208.
2. Moravcová J, Rulcová J, Polák J, Zemanová Z, Klamová H, Haskovec C. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib. Leuk Res. 2005; 29:1365–1366. PMID: 15876454.
3. Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L, et al. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript. Cancer Genet Cytogenet. 2007; 174:111–115. PMID: 17452251.
Article
4. Masuko M, Furukawa T, Abe T, Wada R, Maruyama S, Kitajima T, et al. A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement. Int J Hematol. 2009; 90:230–234. PMID: 19565180.
Article
5. Achkar WA, Wafa A, Ali BY, Manvelyan M, Liehr T. A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes. Oncol Lett. 2010; 1:797–800. PMID: 22966382.
Article
6. McCarron SL, Langabeer SE, Bolger K, Haslam K, Crampe M, Kelly J, et al. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion. Med Oncol. 2015; 32:452. PMID: 25579165.
Article
7. Franz WM, Berger P, Wang JY. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 1989; 8:137–147. PMID: 2496972.
Article
8. Kato JY, Takeya T, Grandori C, Iba H, Levy JB, Hanafusa H. Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein. Mol Cell Biol. 1986; 6:4155–4160. PMID: 2432397.
Article
9. Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P, et al. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood. 1998; 91:406–418. PMID: 9427693.
Article
10. Gross AW, Zhang X, Ren R. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol Cell Biol. 1999; 19:6918–6928. PMID: 10490629.
Article
Full Text Links
  • ALM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr